AdaptHealthvsMerck & Company

AHCO and MRK stock compared: price, dividend, valuation and results, from SEC filings.

AHCO

AdaptHealth Corp.

$7.25

Value $986M

-1.56%
AHCO's page

MRK

Merck & Company, Inc.

$133.88

Value $331B

-2.97%
MRK's page

AdaptHealth (AHCO) has a market value of $986M and Merck & Company (MRK) $331B. Over the last year, with dividends, AHCO moved -20.2% and MRK +42.9%. Dividend yield: AHCO none, MRK 2.54%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AHCO$986M

    MRK$331B

    MRK is 336 times AHCO

  • Revenue, 12 months

    AHCO$3.4B

    MRK$67.4B

    MRK is 20 times AHCO

  • Net income, 12 months

    AHCO-$407M

    MRK$2.5B

  • Operating margin

    AHCO-9.6%

    MRK–

  • ROIC

    AHCO-8.0%

    MRK3.9%

    11.9 points apart

  • P/E

    AHCO–

    MRK134.9

  • Dividend yield

    AHCO0.0%

    MRK2.5%

    2.5 points apart

  • 5-year return

    AHCO-68.9%

    MRK+87.8%

    156.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AHCO-68.9%

MRK+87.8%

10020020222023202420252026
Returns by period
PeriodAHCOWith dividendsMRKWith dividends
1 year since November 18, 2025-20.2%Price -20.2%+42.9%Price +38.8%
3 years since November 17, 2023-14.9%-5.2% a yearPrice -14.9%+44.2%+13.0% a yearPrice +31.6%
5 years since November 18, 2021-68.9%-20.8% a yearPrice -68.9%+87.8%+13.4% a yearPrice +61.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AHCOAdaptHealthMRKMerck & Company

Valuation

AHCOMRK
Valuation
Price$7.25$133.88
Market value$986M$331B
Enterprise value (EV)$2.9B$375B
P/E–134.9
P/E, 5-year median36.514.8
P/B0.87.4
EV/EBIT–78.8
Free cash flow yield8.3%4.5%

Results and growth

AHCOMRK
Results and growth
Revenue, 12 months$3.4B$67.4B
Net income, 12 months-$407M$2.5B
Free cash flow, 12 months$82M$14.7B
Earnings per share, 12 months-$2.98$0.98
Revenue growth, year on year-0.5%1.3%
Revenue growth a year, past+25.2%over 5 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

AHCOMRK
Margins and returns on capital
Gross margin15.8%71.8%
Operating margin-9.6%–
Net margin-11.8%3.6%
ROIC-8.0%3.9%
ROE-28.1%5.2%

Balance sheet

AHCOMRK
Balance sheet
Cash–$9.7B
Total debt$2.0B$53.8B
Net debt / EBITDA36.85.7
Interest cover-3.2×2.4×

Dividends and buybacks

AHCOMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.5%
Shareholder yield–4.1%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AHCO or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, AdaptHealth or Merck & Company?

By market value, Merck & Company ($331B) is about 335.7 times AdaptHealth ($986M), at today's prices.

How did AHCO and MRK stock do over the last 5 years?

Since November 18, 2021, AHCO's price moved -68.9% and MRK's +61.2%. With dividends: AHCO -68.9% (-20.8% a year), MRK +87.8% (+13.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, AHCO or MRK?

The dividend yield at today's price is none for AdaptHealth and 2.54% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, AdaptHealth or Merck & Company?

Over the last twelve months, the net margin was -11.8% for AdaptHealth and 3.6% for Merck & Company, and the operating margin -9.6% and –. Revenue was $3.4B and $67.4B.

Which is the better investment, AdaptHealth or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.